The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Open accessAbstract
Therapies that target the programmed death-1 (PD-1) receptor have shown unprecedented rates of durable clinical responses in patients with various cancer types. One mechanism by which cancer tissues limit the host immune response is via upregulation of PD-1 ligand (PD-L1) and its ligation to PD-1 on antigen-specific CD8+ T cells (termed adaptive immune resistance). Here we show that pre-existing CD8+ T cells distinctly located at the invasive tumour margin are associated with expression of the PD-1/PD-L1 immune inhibitory axis and may predict response to therapy. We analysed samples from 46 patients with metastatic melanoma obtained before and during anti-PD-1 therapy (pembrolizumab) using quantitative immunohistochemistry, quantitative multiplex immunofluorescence, and next-generation sequencing for T-cell antigen receptors (TCRs). In serially sampled tumours, patients responding to treatment showed proliferation of intratumoral CD8+ T cells that directly correlated with radiographic reduction in tumour size. Pre-treatment samples obtained from responding patients showed higher numbers of CD8-, PD-1- and PD-L1-expressing cells at the invasive tumour margin and inside tumours, with close proximity between PD-1 and PD-L1, and a more clonal TCR repertoire. Using multivariate analysis, we established a predictive model based on CD8 expression at the invasive margin and validated the model in an independent cohort of 15 patients. Our findings indicate that tumour regression after therapeutic PD-1 blockade requires pre-existing CD8+ T cells that are negatively regulated by PD-1/PD-L1-mediated adaptive immune resistance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, both PDL-1 expression and TMB fail to encapsulate various tumor microenvironmental features influencing ICI responses15–17.”
From Predicting the tumor microenvironment composition and immunotherapy response in non-small cell lung cancer from digital histopathology images (2024) · cites this paper as [15]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Pre-treatment CD8+ T cell presence is linked to responses to ICB and anti-PD-1 plus lenvatinib in HCC patients.”
From Contrasting cytotoxic and regulatory T cell responses underlying distinct clinical outcomes to anti-PD-1 plus lenvatinib therapy in cancer (2025) · cites this paper as [4]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“We compared the tumor-associated immune infiltrates via multi-parameter immunohistochemistry (IHC) and observed a higher density of CD8+ T cells in baseline samples of R versus NR (p=0.04), consistent with prior reports (Fig. 4A and fig. S18) (18, 37).”
From Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients (2018) · cites this paper as [37]
In the citing paper
“Additionally, cancer cells can increase immune checkpoint molecules such as PD-L1, resulting in peripheral T cell exhaustion and the inhibition of malignant cell apoptosis [85].”
From Current and Future Trends of Colorectal Cancer Treatment: Exploring Advances in Immunotherapy (2024) · cites this paper as [85]
In the citing paper
“Indeed, as mentioned in the previous section, both PD-1 and CTLA-4 blockades are more effective in tumors that are infiltrated by T cells or that have high mutation rates and are therefore more immunogenic prior to treatment (86–88).”
From Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations (2018) · cites this paper as [88]
In the citing paper
“An increase in CD8+ T cell proliferation within the tumor lesion and an increased frequency of Th9 cells in the patients’ circulation were also associated with treatment response (88, 91, 92).”
From Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations (2018) · cites this paper as [88]
In the citing paper
“Other pre-treatment immunological factors associated with improved treatment responses include high eosinophil and lymphocyte blood counts, an abundance of CD8+ T cells infiltrating the tumor or present at the tumor margin, and increased serum TGF-β levels in melanoma patients treated with anti-PD-1 (88, 91, 92, 109).”
From Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations (2018) · cites this paper as [88]
In the citing paper
“TILs are therefore under active investigation as a biomarker to guide selection of patients for treatment with ICT, although significant variability exists in definitions and thresholds (149, 150).”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [149]
In the citing paper
“The presence of CD8+ T cells at tumor margins and within the tumor prior to treatment with checkpoint inhibitors was associated with a stronger response to treatment (Tumeh et al., 2014).”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Tumeh et al., 2014
In the citing paper
“abundance of T cells at the invasive tumor margin prior to treatment was associated with a better response, whereas upon treatment, T cell densities were increased both at the margin and within the tumor parenchyma in responding patients”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Tumeh et al., 2014
In the citing paper
“In metastatic melanoma patients, a higher density of intratumoral CD8+ T cells at baseline was shown to predict favorable response to anti-PD-1 treatment”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Tumeh et al., 2014
In the citing paper
“some studies have found that high TCR diversity in peripheral blood and tumors prior to ICI therapy is predictive of effective treatment, others have pointed to ICI therapy-associated increases in TCR clonality, that is, enrichment of T cells with the same TCRs, as a sign of effective therapy (150, 157-161).”
From Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance (2021) · cites this paper as [150]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516
Nivolumab plus Ipilimumab in Advanced Melanoma
Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302369 · Cited by 4,230
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
Hamid, O., Robert, C., DAUD, A. I., Hodi, F. S., Hwu, W., Kefford, R. F., Wolchok, J. D., Hersey, P., Joseph, R. W., Weber, J. S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305133 · Cited by 3,427
Self-citationIntratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer
Zhang, L., Conejo-Garcia, J. R., Katsaros, D., Gimotty, P. A., Massobrio, M., Regnani, G., Makrigiannakis, A., Gray, H., Schlienger, K., Liebman, M. N., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020177 · Cited by 3,397
Wolchok, J. D., Hoos, A., O'Day, S. J., Weber, J. S., Hamid, O., Lebbé, C., Maio, M., Binder, M., Bohnsack, O., Nichol, G. M., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1624 · Cited by 3,214
Flagged first, then by citations
Cited by
Sorted by citations
Items 101–200 of 1,060
Sun, R., Limkin, E. J., Vakalopoulou, M., Dercle, L., Champiat, S., Han, S. R., Verlingue, L., Brandao, D., Lancia, A., Ammari, S., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30413-3 · Cited by 1,236
Self-citationImmunological hallmarks of stromal cells in the tumour microenvironment
Turley, S. J., Cremasco, V., & Astarita, J. L. (2015) · Nature Reviews Immunology · doi:10.1038/nri3902 · Cited by 1,140
Toward personalized treatment approaches for non-small-cell lung cancer
Wang, M., Herbst, R. S., & Boshoff, C. (2021) · Nature Medicine · doi:10.1038/s41591-021-01450-2 · Cited by 1,127
Hegde, P. S., Karanikas, V., & Evers, S. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1507 · Cited by 1,000
Radiotherapy and immunotherapy: a beneficial liaison?
Weichselbaum, R. R., Liang, H. L., Deng, L., & Fu, Y. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.211 · Cited by 1,091
CD8+ T cell differentiation and dysfunction in cancer
Philip, M., & Schietinger, A. (2022) · Nature Reviews Immunology · doi:10.1038/s41577-021-00574-3 · Cited by 1,052
Pitt, J. M., Vétizou, M., Daillère, R., Roberti, M. P., Yamazaki, T., Routy, B., Lepage, P., Boneca, I. G., Chamaillard, M., Kroemer, G., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.06.001 · Cited by 1,060
Liu, D., Schilling, B., Liu, D., Sucker, A., Livingstone, E., Jerby-Arnon, L., Zimmer, L., Gutzmer, R., Satzger, I., Loquai, C., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0654-5 · Cited by 1,039
“…to ICB in melanoma have been proposed, including tumor mutation and neoantigen burden (TMB) 8-11 , immunohistological detection of PD-L1/CD8 12 , and genetic alterations affecting antigen presentation 13,14 , interferon-gamma signalling pathways 15 , alternative survival and proliferation…”
Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab), Savas, P., Virassamy, B., Ye, C., Salim, A., Mintoff, C. P., Caramia, F., Salgado, R., Byrne, D. J., Teo, Z. L., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0078-7 · Cited by 992
Chen, P.-L., Roh, W., Reuben, A., Cooper, Z. A., Spencer, C. N., Prieto, P. A., Miller, J. P., Bassett, R. L., Gopalakrishnan, V., Wani, K., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1545 · Cited by 988
Ma, X., Xiao, L., Liu, L., Ye, L., Pan, S., Bi, E., Wang, Q., Yang, M., Qian, J., & Yi, Q. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2021.02.015 · Cited by 1,048
Monitoring immune-checkpoint blockade: response evaluation and biomarker development
Nishino, M., Ramaiya, N. H., Hatabu, H., & Hodi, F. S. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.88 · Cited by 1,023
Rescue of exhausted CD8 T cells by PD-1–targeted therapies is CD28-dependent
Kamphorst, A. O., Wieland, A., Nasti, T., Yang, S., Zhang, R., Barber, D. L., Konieczny, B. T., Daugherty, C. Z., Koenig, L., Yu, K., et al. (2017) · Science · doi:10.1126/science.aaf0683 · Cited by 1,015
In situ sprayed bioresponsive immunotherapeutic gel for post-surgical cancer treatment
Chen, Q., Wang, C., Zhang, X., Chen, G., Hu, Q., Li, H., Wang, J., Wen, D., Zhang, Y., Lü, Y., et al. (2018) · Nature Nanotechnology · doi:10.1038/s41565-018-0319-4 · Cited by 1,029
Resistance to checkpoint blockade therapy through inactivation of antigen presentation
Sade-Feldman, M., Jiao, Y. J., Chen, J. H., Rooney, M. S., Barzily-Rokni, M., Eliane, J.-P., Bjorgaard, S. L., Hammond, M. R., Vitzthum, H., Blackmon, S. M., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01062-w · Cited by 1,005
Neoadjuvant checkpoint blockade for cancer immunotherapy
Topalian, S. L., Taube, J. M., & Pardoll, D. M. (2020) · Science · doi:10.1126/science.aax0182 · Cited by 1,001
“Nonetheless, true intratumoral proliferation of tumor-specific T cells upon PD-1 blockade has not yet been proven in humans, although it has been surmised from findings of increased clonality of TCRs in melanomas after anti–PD-1 therapy (30).”
BackgroundNeoantigens: promising targets for cancer therapy
Xie, N., Shen, G., Gao, W., Huang, Z., Huang, C., & Fu, L. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01270-x · Cited by 1,020
“The quantity and quality of tumor-reactive T cells can be measured and tracked in order to anticipate how well cancer immunotherapy will work.(378,515,516) A multiparameter phenotypic and functional readout of T cell reactivity will be likely necessary in the absence of extensive evaluation using several types of T ce…”
BackgroundAcquired Resistance to Immune Checkpoint Inhibitors
Schoenfeld, A. J., & Hellmann, M. D. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.03.017 · Cited by 991
“PD-L1 expression, tumor mutational burden, tumor infiltrating lymphocytes (TILs) or related gene expression signatures have been explored as potential predictors and various other markers are currently under investigation (Chen et al., 2016; Cristescu et al., 2018; Garon et al., 2015; Hugo et al., 2016; Johnson et al.…”
BackgroundŞenbabaoğlu, Y., Gejman, R. S., Winer, A. G., Liu, M., Allen, E. M. V., de Velasco, G., Miao, D., Ostrovnaya, I., Drill, E. N., Luna, A., et al. (2016) · Genome biology · doi:10.1186/s13059-016-1092-z · Cited by 969
Dong, Z.-Y., Zhong, W.-Z., Zhang, X.-C., Su, J., Xie, Z., Liu, S.-Y., Tu, H.-Y., Chen, H.-J., Sun, Y.-L., Zhou, Q., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2554 · Cited by 959
Potentiating the antitumour response of CD8+ T cells by modulating cholesterol metabolism
Yang, W., Bai, Y., Xiong, Y., Zhang, J., Chen, S., Zheng, X., Meng, X., Li, L., Wang, J., Xu, C., et al. (2016) · Nature · doi:10.1038/nature17412 · Cited by 1,010
Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy
Pfirschke, C., Engblom, C., Rickelt, S., Cortez‐Retamozo, V., Garris, C., Pucci, F., Yamazaki, T., Poirier-Colame, V., Newton, A., Redouane, Y., et al. (2016) · Immunity · doi:10.1016/j.immuni.2015.11.024 · Cited by 971
Combination cancer immunotherapies tailored to the tumour microenvironment
Smyth, M. J., Ngiow, S. F., Ribas, A., & Teng, M. W. L. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.209 · Cited by 944
Self-citationCancer nanomedicine for combination cancer immunotherapy
Nam, J., Son, S., Park, K. S., Zou, W., Shea, L. D., & Moon, J. J. (2019) · Nature Reviews Materials · doi:10.1038/s41578-019-0108-1 · Cited by 955
CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity
Burr, M. L., Sparbier, C. E., Chan, Y.-C., Williamson, J. C., Woods, K., Beavis, P. A., Lam, E. Y. N., Henderson, M. A., Bell, C. C., Stolzenburg, S., et al. (2017) · Nature · doi:10.1038/nature23643 · Cited by 946
Khoja, L., Day, D., Chen, T. W., Siu, L. L., & Hansen, A. R. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx286 · Cited by 952
Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition
Litchfield, K., Reading, J. L., Puttick, C., Thakkar, K., Abbosh, C., Bentham, R., Watkins, T. B. K., Rosenthal, R., Biswas, D., Rowan, A., et al. (2021) · Cell · doi:10.1016/j.cell.2021.01.002 · Cited by 893
Deep learning in cancer diagnosis, prognosis and treatment selection
Tran, K. A., Kondrashova, O., Bradley, A., Williams, E. D., Pearson, J. V., & Waddell, N. (2021) · Genome Medicine · doi:10.1186/s13073-021-00968-x · Cited by 932
“Infiltrating immune cell populations, such as CD4+ and CD8+ T cells, are potential important biomarkers of immunotherapy response [139, 140].”
BackgroundCurrent Challenges in Cancer Treatment
Zugazagoitia, J., Guedes, C., Ponce, S., Ferrer, I., Molina‐Pinelo, S., & Paz-Ares, L. G. (2016) · Clinical Therapeutics · doi:10.1016/j.clinthera.2016.03.026 · Cited by 961
Roh, W., Chen, P.-L., Reuben, A., Spencer, C. N., Prieto, P. A., Miller, J. P., Gopalakrishnan, V., Wang, F., Cooper, Z. A., Reddy, S. M., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aah3560 · Cited by 859
Neoadjuvant-adjuvant or adjuvant-only pembrolizumab in advanced melanoma
Patel, S. P., Othus, M., Chen, Y., Wright, G. P., Yost, K. J., Hyngstrom, J. R., Hu-Lieskovan, S., Lao, C. D., Fecher, L. A., Truong, T.-G., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2211437 · Cited by 919
Self-citationKamphorst, A. O., Pillai, R. N., Yang, S., Nasti, T. H., Akondy, R. S., Wieland, A., Sica, G. L., Yu, K., Koenig, L., Patel, N. T., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1705327114 · Cited by 854
Coinhibitory Pathways in Immunotherapy for Cancer
Baumeister, S. H. C., Freeman, G. J., Dranoff, G., & Sharpe, A. H. (2016) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032414-112049 · Cited by 937
A STING-activating nanovaccine for cancer immunotherapy
Luo, M., Wang, H., Wang, Z., Cai, H., Lu, Z., Li, Y., Du, M., Huang, G., Wang, C., Chen, X., et al. (2017) · Nature Nanotechnology · doi:10.1038/nnano.2017.52 · Cited by 907
Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma
Zhao, J., Chen, A. X., Gartrell, R. D., Silverman, A. M., Aparicio, L., Chu, T., Bordbar, D., Shan, D., Samanamud, J., Mahajan, A., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0349-y · Cited by 903
Single-cell analysis reveals fibroblast clusters linked to immunotherapy resistance in cancer.
Kieffer, Y., Hocine, H. R., Gentric, G., Pelon, F., Bernard, C., Bourachot, B., Lameiras, S., Albergante, L., Bonneau, C., Guyard, A., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1384 · Cited by 910
“In addition to well-known factors involved in immunotherapy resistance, such as lack of antigen presentation, tumor immunogenicity deficiency, T cell exclusion or defective tumor cell response to IFNg (52-55), we identify here specific CAF-S1 cellular clusters as new key players in primary resistance to immunotherapy.”
BackgroundEvolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non–Small Cell Lung Cancer
Anagnostou, V., Smith, K. N., Forde, P. M., Niknafs, N., Bhattacharya, R., White, J. R., Zhang, T., Adleff, V., Phallen, J. A., Wali, N., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0828 · Cited by 918
Freeman-Keller, M., Kim, Y., Cronin, H., Richards, A., Gibney, G., & Weber, J. S. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1136 · Cited by 863
Clinical relevance of host immunity in breast cancer: from TILs to the clinic
Savas, P., Salgado, R., Denkert, C., Sotiriou, C., Darcy, P. K., Smyth, M. J., & Loi, S. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.215 · Cited by 890
Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma
Blank, C. U., Rozeman, E. A., Fanchi, L. F., Sikorska, K., van de Wiel, B., Kvistborg, P., Krijgsman, O., van den Braber, M., Philips, D., Broeks, A., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0198-0 · Cited by 880
Dangaj, D., Bruand, M., Grimm, A. J., Ronet, C., Barras, D., Duttagupta, P. A., Lanitis, E., Duraiswamy, J., Tanyi, J. L., Benencia, F., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.05.004 · Cited by 875
“TILs detection prior to therapy has been associated with response to immune checkpoint blockade in melanoma (Tumeh et al., 2014).”
BackgroundInfluentialBreast Cancer Immunotherapy: Facts and Hopes
Emens, L. A. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-3001 · Cited by 898
Juneja, V. R., McGuire, K. A., Manguso, R. T., LaFleur, M. W., Collins, N. B., Haining, W. N., Freeman, G. J., & Sharpe, A. H. (2017) · The Journal of Experimental Medicine · doi:10.1084/jem.20160801 · Cited by 877
Cancer vaccines: the next immunotherapy frontier
Lin, M. J., Svensson‐Arvelund, J., Lubitz, G. S., Marabelle, A., Melero, I., Brown, B. D., & Brody, J. (2022) · Nature Cancer · doi:10.1038/s43018-022-00418-6 · Cited by 877
Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade
Hsu, J., Hodgins, J. J., Marathe, M., Nicolai, C. J., Bourgeois-Daigneault, M.-C., Trevino, T. N., Azimi, C. S., Scheer, A. K., Randolph, H. E., Thompson, T. W., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci99317 · Cited by 817
Chemokines and the immune response to cancer
Ozga, A. J., Chow, M. T., & Luster, A. D. (2021) · Immunity · doi:10.1016/j.immuni.2021.01.012 · Cited by 884
Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma
Amaria, R. N., Reddy, S. M., Tawbi, H. A., Davies, M. A., Ross, M. I., Glitza, I. C., Cormier, J. N., Lewis, C., Hwu, W.-J., Hanna, E., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0197-1 · Cited by 835
Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo
Rafiq, S., Yeku, O. O., Jackson, H. J., Purdon, T. J., van Leeuwen, D. G., Drakes, D. J., Song, M., Miele, M. M., Li, Z., Wang, P., et al. (2018) · Nature Biotechnology · doi:10.1038/nbt.4195 · Cited by 833
Tumour-targeting bacteria engineered to fight cancer
Zhou, S., Gravekamp, C., Bermudes, D., & Liu, K. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0070-z · Cited by 821
Intratumoral heterogeneity in cancer progression and response to immunotherapy
Vitale, I., Shema, E., Loi, S., & Galluzzi, L. (2021) · Nature Medicine · doi:10.1038/s41591-021-01233-9 · Cited by 848
An intra-tumoral niche maintains and differentiates stem-like CD8 T cells
Jansen, C. S., Prokhnevska, N., Master, V. A., Sanda, M. G., Carlisle, J. W., Bilen, M. A., Cardenas, M. A., Wilkinson, S. C., Lake, R. G., Sowalsky, A. G., et al. (2019) · Nature · doi:10.1038/s41586-019-1836-5 · Cited by 826
A single-cell map of intratumoral changes during anti-PD1 treatment of patients with breast cancer
Bassez, A., Vos, H., Van Dyck, L., Floris, G., Arijs, I., Desmedt, C., Boeckx, B., Vanden Bempt, M., Nevelsteen, I., Lambein, K., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01323-8 · Cited by 867
Combined antiangiogenic and anti–PD-L1 therapy stimulates tumor immunity through HEV formation
Allen, E., Jabouille, A., Rivera, L. B., Lodewijckx, I., Missiaen, R., Steri, V., Feyen, K., Tawney, J., Hanahan, D., Michael, I. P., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aak9679 · Cited by 820
Next generation of immune checkpoint therapy in cancer: new developments and challenges
Marin-Acevedo, J. A., Dholaria, B., Soyano, A. E., Knutson, K. L., Chumsri, S., & Lou, Y. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0582-8 · Cited by 819
Hendry, S. A., Salgado, R., Gevaert, T., Russell, P. A., John, T., Thapa, B., Christie, M., de Vijver, K. K. V., Estrada, M. V., Ericsson, P. I. G., et al. (2017) · Advances in Anatomic Pathology · doi:10.1097/pap.0000000000000161 · Cited by 815
Self-citationKumagai, S., Togashi, Y., Kamada, T., Sugiyama, E., Nishinakamura, H., Takeuchi, Y., Kochin, V., Itahashi, K., Maeda, Y., Matsui, S., et al. (2020) · Nature Immunology · doi:10.1038/s41590-020-0769-3 · Cited by 823
House, I. G., Savas, P., Lai, J., Chen, A. X. Y., Oliver, A. J., Teo, Z. L., Todd, K. L., Henderson, M. A., Giuffrida, L., Petley, E. V., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1868 · Cited by 790
“Factors that have been reported to predict responses to immune checkpoint inhibitors include the mutational load of the tumor (3), the expression of target ligands such as PD-L1, and the presence of high number of TILs (4).”
BackgroundThe Next Decade of Immune Checkpoint Therapy
Sharma, P., Siddiqui, B. A., Anandhan, S., Yadav, S. S., Subudhi, S. K., Gao, J., Goswami, S., & Allison, J. P. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1680 · Cited by 750
Enhanced Cancer Immunotherapy by Microneedle Patch-Assisted Delivery of Anti-PD1 Antibody
Wang, C., Ye, Y., Hochu, G. M., Sadeghifar, H., & Gu, Z. (2016) · Nano Letters · doi:10.1021/acs.nanolett.5b05030 · Cited by 794
mRNA-based therapeutics: powerful and versatile tools to combat diseases
Qin, S., Tang, X., Chen, Y., Chen, K., Fan, N., Xiao, W., Zheng, Q., Li, G., Teng, Y., Wu, M., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01007-w · Cited by 852
Ott, P. A., Hu-Lieskovan, S., Chmielowski, B., Govindan, R., Naing, A., Bhardwaj, N., Margolin, K., Awad, M. M., Hellmann, M. D., Lin, J. J., et al. (2020) · Cell · doi:10.1016/j.cell.2020.08.053 · Cited by 738
The head and neck cancer immune landscape and its immunotherapeutic implications
Mandal, R., Şenbabaoğlu, Y., Desrichard, A., Havel, J. J., Dalin, M. G., Riaz, N., Lee, K.-W., Ganly, I., Hakimi, A. A., Chan, T. A.-T., et al. (2016) · JCI Insight · doi:10.1172/jci.insight.89829 · Cited by 785
Peripheral T cell expansion predicts tumour infiltration and clinical response
Wu, T. D., Madireddi, S., de Almeida, P. E., Banchereau, R., Chen, Y.-J. J., Chitre, A. S., Chiang, E. Y., Iftikhar, H., O’Gorman, W. E., Au-Yeung, A., et al. (2020) · Nature · doi:10.1038/s41586-020-2056-8 · Cited by 770
Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors
Yi, M., Jiao, D., Xu, H., Liu, Q., Zhao, W., Han, X., & Wu, K. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0864-3 · Cited by 764
D'Angelo, S. P., Mahoney, M. R., Van Tine, B. A., Atkins, J., Milhem, M. M., Jahagirdar, B. N., Antonescu, C. R., Horvath, E., Tap, W. D., Schwartz, G. K., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30006-8 · Cited by 759
Limkin, E. J., Sun, R., Dercle, L., Zacharaki, E. I., Robert, C., Reuzé, S., Schernberg, A., Nikos Paragios, A., Deutsch, É., & Ferté, C. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx034 · Cited by 756
Self-citationThe future of cancer immunotherapy: microenvironment-targeting combinations
Murciano‐Goroff, Y. R., Warner, A. B., & Wolchok, J. D. (2020) · Cell Research · doi:10.1038/s41422-020-0337-2 · Cited by 768
Li, J., Byrne, K. T., Yan, F., Yamazoe, T., Chen, Z., Baslan, T., Richman, L. P., Lin, J., Sun, Y. H., Rech, A. J., et al. (2018) · Immunity · doi:10.1016/j.immuni.2018.06.006 · Cited by 746
The Tumor Microenvironment: A Milieu Hindering and Obstructing Antitumor Immune Responses
Labani‐Motlagh, A., Ashja-Mahdavi, M., & Loskog, A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00940 · Cited by 782
Blank, C. U., Haanen, J. B., Ribas, A., & Schumacher, T. N. (2016) · Science · doi:10.1126/science.aaf2834 · Cited by 748
Loss of ADAR1 in tumours overcomes resistance to immune checkpoint blockade
Ishizuka, J. J., Manguso, R. T., Cheruiyot, C. K., Bi, K., Panda, A., Iracheta-Vellve, A., Miller, B. C., Du, P. P., Yates, K. B., Dubrot, J., et al. (2019) · Nature · doi:10.1038/s41586-018-0768-9 · Cited by 697
Chow, M. T., Ozga, A. J., Servis, R. L., Frederick, D. T., Lo, J. A., Fisher, D. E., Freeman, G. J., Boland, G. M., & Luster, A. D. (2019) · Immunity · doi:10.1016/j.immuni.2019.04.010 · Cited by 716
“A Functional CD8 T Cell Response after PD-1 Blockade Is Dependent on CXCR3 Given the reported role of CXCR3 in T cell recruitment into tumors and the importance of pre-existing intratumoral CD8 T cells for effective PD-1 blockade therapy (Tumeh et al., 2014), we hypothesized that the reduced therapeutic effect of anti…”
WNT/β-catenin pathway activation correlates with immune exclusion across human cancers
Luke, J. J., Bao, R., Sweis, R. F., Spranger, S., & Gajewski, T. F. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1942 · Cited by 722
“Solid tumor histologies can be segregated based on the degree of the T-cell-inflamed tumor microenvironment gene expression signature Strong associations have been observed between the presence of T-cell-infiltration and/or a T-cell-inflamed gene expression signature and response to immune-checkpoint blockade (10, 21).”
BackgroundThe clinical role of the TME in solid cancer
Giraldo, N. A., Sánchez-Salas, R., Peske, J. D., Vano, Y. A., Becht, É., Petitprez, F., Validire, P., Ingels, A., Cathelineau, X., Fridman, W. H., et al. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0327-z · Cited by 756
Intratumoral CD4+ T Cells Mediate Anti-tumor Cytotoxicity in Human Bladder Cancer
Oh, D. Y., Kwek, S. S., Raju, S. S., Li, T., McCarthy, E., Chow, E., Aran, D., Ilano, A., Pai, C.-C. S., Rancan, C., et al. (2020) · Cell · doi:10.1016/j.cell.2020.05.017 · Cited by 734
Bender, M. J., McPherson, A. C., Phelps, C. M., Pandey, S. P., Laughlin, C. R., Shapira, J. H., Medina Sanchez, L., Rana, M., Richie, T. G., Mims, T. S., et al. (2023) · Cell · doi:10.1016/j.cell.2023.03.011 · Cited by 732
“…T cell receptors Tigit , Pdcd1 , and Lag3 in tumor-infiltrating CD8 T cells (Figure 1K), in concert with the observation that human melanoma-infiltrating PD1-express-ing CD8 T cells are positive predictive biomarkers for a PD1 therapy, 23 prompted us to assess the role of Lr in potentiating ICI.”
Vaccines for established cancer: overcoming the challenges posed by immune evasion
van der Burg, S. H., Arens, R., OSSENDORP, F. A., van Hall, T., & Melief, C. J. M. (2016) · Nature reviews. Cancer · doi:10.1038/nrc.2016.16 · Cited by 731
Hendry, S. A., Salgado, R., Gevaert, T., Russell, P. A., John, T., Thapa, B., Christie, M., de Vijver, K. K. V., Estrada, M. V., Ericsson, P. I. G., et al. (2017) · Advances in Anatomic Pathology · doi:10.1097/pap.0000000000000162 · Cited by 720
Self-citationCold and hot tumors: from molecular mechanisms to targeted therapy
Wu, B., Zhang, B., Li, B., Wu, H., & Jiang, M. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01979-x · Cited by 811
Lin, J., Izar, B., Wang, S., Yapp, C., Mei, S., Shah, P., Santagata, S., & Sorger, P. K. (2018) · eLife · doi:10.7554/elife.31657 · Cited by 685
Chakravarthy, A., Khan, L., Bensler, N. P., Bose, P., & De Carvalho, D. D. (2018) · Nature Communications · doi:10.1038/s41467-018-06654-8 · Cited by 656
A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma
Huang, A. C. C., Orlowski, R. J., Xu, X., Mick, R., George, S. M., Yan, P., Manne, S., Kraya, A., Wubbenhorst, B. S., Dorfman, L. M., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0357-y · Cited by 696
Self-citationTan, W. C. C., Nerurkar, S. N., Cai, H. Y., Ng, H. H. M., Wu, D., Wee, F. Y. T., Lim, J. C. T., Yeong, J. P.-S., & Lim, T. K. H. (2020) · 癌症：英文版 · doi:10.1002/cac2.12023 · Cited by 707
“[129] Melanoma 2014 CD8, CD4, Ki-67, PD-1, PD-L1”
Improving cancer immunotherapy using nanomedicines: progress, opportunities and challenges
Martin, J. D., Cabral, H., Stylianopoulos, T., & Jain, R. K. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0308-z · Cited by 691
Li, Z., Lai, X., Fu, S., Ren, L. F., Cai, H., Zhang, H., Gu, Z., Ma, X., & Luo, K. (2022) · Advanced Science · doi:10.1002/advs.202201734 · Cited by 704
Challenges and Opportunities for Pancreatic Cancer Immunotherapy
Bear, A. S., Vonderheide, R. H., & O'Hara, M. H. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.08.004 · Cited by 674
Impact of oncogenic pathways on evasion of antitumour immune responses
Spranger, S., & Gajewski, T. F. (2018) · Nature reviews. Cancer · doi:10.1038/nrc.2017.117 · Cited by 675
Arlauckas, S. P., Garris, C. S., Kohler, R. H., Kitaoka, M., Cuccarese, M. F., Yang, K. S., Miller, M. A., Carlson, J. C., Freeman, G. J., Anthony, R. M., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aal3604 · Cited by 669
Fridman, W. H., Meylan, M., Petitprez, F., Sun, C., Italiano, A., & Sautès‐Fridman, C. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00619-z · Cited by 710
Immunotherapy in Non–Small Cell Lung Cancer: Facts and Hopes
Doroshow, D. B., Sanmamed, M. F., Hastings, K., Politi, K. A., Rimm, D. L., Chen, L., Melero, I., Schalper, K. A., & Herbst, R. S. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1538 · Cited by 666
Daud, A. I., Wolchok, J. D., Robert, C., Hwu, W.-J., Weber, J. S., Ribas, A., Hodi, F. S., Joshua, A. M., Kefford, R., Hersey, P., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.2477 · Cited by 665
Self-citationCD8 T Cell Exhaustion in Chronic Infection and Cancer: Opportunities for Interventions
Hashimoto, M., Kamphorst, A. O., Im, S. J., Kissick, H. T., Pillai, R. N., Ramalingam, S. S., Araki, K., & Ahmed, R. (2018) · Annual Review of Medicine · doi:10.1146/annurev-med-012017-043208 · Cited by 674
Burr, M. L., Sparbier, C. E., Chan, K. L., Chan, Y.-C., Kersbergen, A. J., Lam, E. Y. N., Azidis-Yates, E., Vassiliadis, D., Bell, C. C., Gilan, O., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.08.008 · Cited by 671
“Cancer Cell 36, 1–17, O This is an open access article und recognize and kill cells displaying foreign antigens bound to MHC class I (MHC-I) molecules (Gubin et al., 2014; Tumeh et al., 2014).”
BackgroundFares, C. M., Allen, E. M. V., Drake, C. G., Allison, J. P., & Hu‐Lieskovan, S. (2019) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_240837 · Cited by 665
A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy
Łuksza, M., Riaz, N., Makarov, V., Balachandran, V. P., Hellmann, M. D., Solovyov, A., Rizvi, N. A., Merghoub, T., Levine, A. J., Chan, T. A.-T., et al. (2017) · Nature · doi:10.1038/nature24473 · Cited by 655
DNA Damage and Repair Biomarkers of Immunotherapy Response
Mouw, K. W., Goldberg, M. S., Konstantinopoulos, P. A., & D’Andrea, A. D. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0226 · Cited by 664
Melanoma Cell-Intrinsic PD-1 Receptor Functions Promote Tumor Growth
Kleffel, S., Posch, C., Barthel, S. R., Mueller, H., Schlapbach, C., Guenova, E., Elco, C. P., Lee, N., Juneja, V. R., Zhan, Q., et al. (2015) · Cell · doi:10.1016/j.cell.2015.08.052 · Cited by 672
Koyama, S., Akbay, E. A., Li, Y. Y., Aref, A. R., Skoulidis, F., Herter-Sprie, G. S., Buczkowski, K. A., Liu, Y., Awad, M. M., Denning, W. L., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-1439 · Cited by 640
Evolving synergistic combinations of targeted immunotherapies to combat cancer
Melero, I., Berman, D. M., Aznar, M. A., Korman, A. J., Perez‐Gracia, J. L., & Haanen, J. B. A. G. (2015) · Nature reviews. Cancer · doi:10.1038/nrc3973 · Cited by 641
Cancer immunotherapies targeting the PD-1 signaling pathway
Iwai, Y., Hamanishi, J., Chamoto, K., & Honjo, T. (2017) · Journal of Biomedical Science · doi:10.1186/s12929-017-0329-9 · Cited by 656
Metadata
- Authors
- Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., West, A. N., Carmona, M., Kivork, C., Seja, E., Cherry, G., Gutierrez, A. J., Grogan, T. R., Mateus, C., Tomasic, G., Glaspy, J. A., Emerson, R. O., Robins, H., Pierce, R. H., Elashoff, D. A., Robert, C., & Ribas, A.
- Affiliations
- University of California, Los Angeles (US)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Inserm (FR)
- Adaptive Biotechnologies (United States) (US)
- Fred Hutch Cancer Center (US)
- Corresponding author
- Tumeh, Paul C.
- Ribas, Antoni
- ORCID
- Venue
- Nature
- Published
- 2014-11-26
- Volume
- 515
- Issue
- 7528
- Pages
- 568-571
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC4246418
- OpenAlex
- W2039123767
- Semantic Scholar
- 2c96ca62d538ff43fce01bc848fc018f6ae2b4a0
- Cited by
- 6,609
- References
- 24
- Citations by year
- 2026: 280 · 2025: 398 · 2024: 491 · 2023: 588 · 2022: 695 · 2021: 768 · 2020: 800 · 2019: 610 · 2018: 593 · 2017: 566 · 2016: 488 · 2015: 303 · 2014: 12
- FWCI
- 220.45
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- Howard Hughes Medical Institute
- American Association for Cancer Research (SU2C-AACR-DT1012)
- Cancer Research Institute (SU2C-AACR-DT1012, CA16042)
- Melanoma Research Alliance (SU2C-AACR-DT1012)
- Adaptive Biotechnologies
- Institut Gustave-Roussy
- Sociedad Española de Oncología Médica
- National Institutes of Health (UL1TR000124, 5u54ca119347-03, P30 CA- 16042, SU2C-AACR-DT1012, CA16042)
- Stand Up To Cancer (SU2C-AACR-DT1012))
- National Cancer Institute (U54-CA119347, P01CA168585, P30-CA16042, R01CA170689, P30CA016042)
- National Institute of Allergy and Infectious Diseases (K08AI091663)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- pembrolizumab, adaptive immune resistance, CD8+ T cells, PD-L1, PD-1/PD-L1 axis, metastatic melanoma, tumor-infiltrating lymphocytes, T cell receptor repertoire, predictive biomarkers, tumor regression, immune checkpoint inhibitors
- MeSH terms
- Aged, Aged, 80 and over, Female, Humans, Immunotherapy, Male, Melanoma, Middle Aged, Models, Biological, Biomarkers, Gene Expression Regulation, Neoplastic, Multivariate Analysis, Treatment Outcome, CD8-Positive T-Lymphocytes, Cell Proliferation, Adaptive Immunity, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
